ArticleMolecular neurodegeneration2024
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases.
Erratum issuedOpen access · goldAbstract readLetter
In one paragraph
Article in Molecular neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 24 citations in OpenAlex.
- TDP-43 dysfunction facilitates the pathological conversion of tau.Molecular neurodegeneration · 2026Article
- TDP-43 Aggregation: The Healthy-Toxic Balance of the Prion-Like Domain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Molecular signatures and biomarker development for limbic-predominant age-related TDP-43 encephalopathy (LATE).Acta neuropathologica · 2026Review
- Impact of Orchiectomy on Oxidative Stress-Induced Neurodegeneration in the Male Rat Retina: A Proteomic Analysis.Antioxidants (Basel, Switzerland) · 2026Article
- TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathology.Nature communications · 2026Article
- A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of PKN1.Nature communications · 2026Article
- Review
- Amyloid beta pathology induces astrocytic pTDP-43 mislocalization and disrupts TDP-43-regulated cryptic exon transcripts.Frontiers in aging neuroscience · 2026Article
- TDP-43-mediated alternative polyadenylation is associated with a reduction in VPS35 and VPS29 expression in frontotemporal dementia.PLoS biology · 2026Article
- Sensitivity to TDP-43 loss and degradation resistance determine cryptic exon biomarker potential.bioRxiv : the preprint server for biology · 2025Article
- IsomiR Utility in Amyotrophic Lateral Sclerosis Prognostication.medRxiv : the preprint server for health sciences · 2025Article
- A tabletop blast device for the study of the long-term consequences of traumatic brain injury on brain organoids.Cell reports methods · 2025Article
- Design considerations for C9orf72 disease prevention trials.Brain : a journal of neurology · 2025Review
- Broad brain biodistribution conferred by an AAV to restore TDP-43 function mitigates Frontotemporal Demenia-like deficits.bioRxiv : the preprint server for biology · 2025Article
- Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction.bioRxiv : the preprint server for biology · 2025Article
- Symptomatic treatment by a BBB-permeable AAV engineered to restore TDP-43 function slows motor neuron disease and prevents paralysis.bioRxiv : the preprint server for biology · 2025Article
- TDP-43 pathology induces CD8bioRxiv : the preprint server for biology · 2025Article
- Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions.Molecular neurodegeneration · 2025Review
- Extracellular vesicles in TDP-43 proteinopathies: pathogenesis and biomarker potential.Molecular neurodegeneration · 2025Review
- TDP-43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP-43 Proteinopathies.Movement disorders : official journal of the Movement Disorder Society · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 6 institutions in 1 country.
Anna Calliari *Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Lillian M Daughrity *Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Ellen A AlbagliDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Paula Castellanos OteroDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Mei YueDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Karen Jansen-WestDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Naeyma N IslamDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Thomas CaulfieldDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Bailey RawlinsonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Michael DeTureDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Casey CookDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Gregory S DayDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Björn OskarssonDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Aaron D GitlerDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Tania F GendronDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Mercedes PrudencioDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Michael E WardNational Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. wardme@nih.gov.
Yong-Jie ZhangDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. zhang.yongjie@mayo.edu.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. petrucelli.leonard@mayo.edu.ORCID 0000-0003-2959-129X
Mayo Clinic in Arizona · USMayo Clinic in Florida · USWinnMed · USMayo Clinic · USNational Institutes of Health · USStanford University · US
Funding
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI DANIEL H GESCHWIND · 2019 to 2026
$120.9MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5MProject 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6MExpanding insights into FTD disease mechanismsR35NS097273 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2017 to 2024
$10.6MInnovating Yeast and Human Genetics Approaches to Define Mechanisms of Neurodegenerative DiseaseR35NS097263 · NINDS · STANFORD UNIVERSITY · PI GITLER, AARON D. · 2017 to 2024
$8.6MHuman Biomarkers CoreU54NS123743 · NINDS · STANFORD UNIVERSITY · PI FRATTA, PIETRO, GITLER, AARON D. · 2021 to 2025
$8.2MUnderstanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5MStathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementiasRF1NS120992 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Keith A Josephs, Mercedes Prudencio · 2021 to 2026
$4.2MPoly(ADP-ribose) promotes the condensation and toxicity of C9orf72 arginine-rich dipeptide repeat proteinsR01NS117461 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Tania France Gendron, Yongjie Zhang · 2021 to 2026
$2.9MStathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementiasR01NS120992 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, PRUDENCIO, MERCEDES · 2024 to 2025
$1.6MGlycogen promotes protein aggregation in ALS and FTDR21NS127331 · NINDS · MAYO CLINIC JACKSONVILLE · PI ZHANG, YONGJIE · 2022 to 2022
$430kNIA NIH HHS 5P30AG0062677NIA NIH HHS R01 AG037491NIA NIH HHS R01AG37491NIA NIH HHS U19AG063911NINDS NIH HHS P01 NS084974NINDS NIH HHS P01NS084974NINDS NIH HHS R01 NS117461NINDS NIH HHS R01NS117461NINDS NIH HHS R01 NS120992NINDS NIH HHS R21 NS127331NINDS NIH HHS R21NS127331NINDS NIH HHS R35 NS097263NINDS NIH HHS R35NS097263(10,10)NINDS NIH HHS R35 NS097273NINDS NIH HHS R35NS097273 (17,24)NINDS NIH HHS RF1 NS120992NINDS NIH HHS RF1NS120992NINDS NIH HHS U54NS123743
Abstract
This letter demonstrates the potential of novel cryptic proteins resulting from TAR DNA-binding protein 43 (TDP-43) dysfunction as markers of TDP-43 pathology in neurodegenerative diseases.
Indexed as
Amyotrophic Lateral SclerosisNeurodegenerative DiseasesDNA-Binding ProteinsHumansDNA-Binding Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.